Skip to main content
OpenTrials
Completed

NCT Number: NCT04470648

COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey

Study of COVID-19 seroprevalence in precarious population living in shelters of Samusocial de Paris and in staff working in these centers during COVID-19 epidemic.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Haltes pour femmes, Paris, France

Loading trial locations.

About this study

After emergence of a new coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2, SARS-CoV2) responsible for a cluster of respiratory infection at Wuhan, China, on January, 7th 2020, first cases were diagnosed in France in January 24th 2020.

Health care components of Samusocial de Paris (Lits Haltes Soins Santé (LHSS)) were created in 2006. They provide medical care for homeless people and people in social distress not needing an hospitalization. Sometimes there are 3 persons in a bedroom.

In december 2018, a special shelter for isolated women or women in precarious situations opened.

Because of the living conditions in these centers and the difficulty for these populations to respect social distancing and hygiene recommendations.

A first case of COVID-19 was identified on March 8th 2020 in one of these healthcare centers. Other cases were detected in the same center, then in another center on March 16th, then in the dormitory of the women shelter on March 30th.

A recent study showed an important prevalence of SARS-COV2 in residents of a homeless shelter in Boston (36%), most of them were asymptomatic.

Seroprevalence studies are done in general population or in health care workers, but don't include vulnerable people.

It seemed important to us to describe the epidemic in these centers and to study COVID-19 seroprevalence in these particular populations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • to have been hosted or working in one the three centers (LHSS Ridder-Plaisance or Saint Michel or Halte femmes) between march and may 2020
  • to be aged 18 y or more
  • to be able to give an informed consent

Exclusion criteria

  • people who refuse to participate
  • not being able to give an informed consent
  • Person subject to a legal protection measure (safeguard of justice, curatorship or guardianship)
  • Person who does not understand the information provided on how to carry out the research
  • Obstacle to venous sampling

Treatment and study plan

blood test for SARS-COV2 serology

Diagnostic Test

each person who will accept to participate will have a bood test for a SARS-COV2 serology

Primary outcomes

  1. SARS-COV-2 seroprevalence in 3 centers for homeless and people in social distress

    Time frame: 6 months

    Primary objective is to evaluate SARS-COV2 seroprevalence in people hosted and health care workers of 3 centers of Samusocial de Paris where COVID19 epidemics occured

Secondary outcomes

  1. Morbidity rate

    Time frame: 6 months

    Measure of morbidity in the participating population in the 3 centers

  2. Covid-19 related death rate in the 3 centers from March to May 2020

    Time frame: 6 months

    Number of deaths related to Covid-19 during the epidemic in the 3 centers

  3. Ratio of negative serology rate and positive serology rate in the 3 centers

    Time frame: 6 months

  4. Ratio of SARS-COV2 seroprevalence obtained in these centers to the estimated seroprevalence in the Ile de France region

    Time frame: 6 months

  5. kinetics of SARS-COV2 antibodies in people with initial positive serology

    Time frame: 10 months

    2 blood tests 4 and 8 months afetr the first one

Sponsors and collaborators

Lead sponsor

Institut National de la Santé Et de la Recherche Médicale, France

Other Gov

Collaborators

  • Assistance Publique - Hôpitaux de Paris
  • Samusocial de Paris

Registry information

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Jul 14, 2020
Registry last updated
Jan 26, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.